|
News for Healthier Living
ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma
ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers - follicular lymphoma and marginal zone lymphoma.
December 8, 2024
December 21 2024December 20 2024December 19 2024December 18 2024December 17 2024December 16 2024December 15 2024December 14 2024December 13 2024December 12 2024December 11 2024December 10 2024December 9 2024December 8 2024
|
|
|
|
|